 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
 |
 |
 |
 |
|
||||||
 |
|
|
|
|
|
 |
|
||||
 |
 |
 |
 |
 |
|
 |
|
||||
 |
|
||||
Jun-9 | |||
8:30 | Registration & Breakfast Pastries with Coffee/Teas | ||
9:00 | Welcome Chairperson's Opening Remarks | ||
| Min Li, PhD, |  |
||
| Associate Professor, Johns Hopkins School of Medicine | |||
Keynote
Address | |||
9:10
| Ion Channels: What HTS Needs |  |
|
| Tina Garyantes, PhD | |
||
| Head of Automated Screening, Aventis Pharmaceuticals | |||
9:55
| Nonradioactive Rubidium Efflux Assay And Emerging Technologies In Ion Channel Drug Discovery | ||
| Georg Terstappen, PhD | |
||
| Vice President, Discovery Research, Siena Biotech | |||
10:40 | Refreshment Break and Poster Viewing | ||
Various
Approaches For Screening Ion Channel Targets | |||
11:00
| New Developments of Non-radioactive Flux Assay for Screening Ion Channels | |
|
| Sikander Gill, PhD | |
||
| Director of Assay Development Aurora Biomed, 1001 E. Pender St., Vancouver, Canada | |||
11:30 | Nonradioactive ion flux assay using Atomic Absorption Spectroscopy for identifying ion channel modulators | |
|
| Shephali Trivedi, PhD | |
||
| Principal Scientist, Astrazeneca, DE | |||
12:00
| Luncheon Break In Ballroom D | ||
1:00 | Pharmacology of a Ligand-Gated Cation Channel: Rb+ Efflux versus Fluorescence, Luminescence, and 45Ca2+ | |
|
| Byron Taylor | |
||
| HTS / Molecular Pharmacology, Amgen | |||
1:30 | Development of Plate Based High Throughput Assays for Voltage Gated Sodium Channels: One size Does Not Fit All. | ||
| David Cronk, PhD | |
||
| Group Leader, Molecular Pharmacology, Ionix Pharmaceuticals Ltd | |||
2:00
| Improving Ion Channel Drug Discovery by Conducting High Throughput Screening in Physiological-Relevant In Vivo Assays | |
|
| Geert Plaetinck, PhD | |
||
Director of Biology, deVGen | |||
2:30
| Refreshment Break and Poster Viewing | ||
3:00 | Alternative Eukaryotic Systems for High Throughput Studies of Ion Channels | ||
| David Fedida, MD, PhD | |
||
| Professor, Dept. Physiology, UBC Sr. Director of Experimental Medicine, Cardiome Pharma Corporation | |||
3:30
| Ion Channel Drug Discovery for Novel Atrial Fibrillation & Pain Drugs | ||
| Pravin R. Chaturvedi, PhD | |
||
| President and CEO, Scion Pharmaceuticals | |||
4:00 | A Novel Platform for Discovery of Therapeutics for Epilepsy | |
|
| Steven Petrou, PhD | |
||
| VP CNS Research, Bionomics, Ltd | |||
4:30 | Structure and Function of a Binary Insecticidal Protein Complex | ||
| Victor Guzov, PhD | |
||
| Senior Research Scientist Monsanto Company | |||
5:00 | Functional Validation and Antagonists Screening for an Oncogenic K+ Channel | |
|
| Lin Pei, PhD | |||
| Scientist, Tularick, Inc. | |||
7:00 | Dinner Function | ||
| Venue : MacDonald Ballroom A | |||
Jun-10 | |||
8:30 | Registration & Breakfast Pastries with Coffee/Teas | ||
9:00
| Chairperson's Recap of Day One | ||
| Georg Terstappen, Vice President, Siena Biotech | |
||
9:10 | BC BIOTECH Executive Director's Remarks | |
|
| Paul Stinson, MBA | |||
Keynote
Address | |||
9:30
| Structure and Molecular Pharmacology of Sodium Ion Channels | |
|
| William Catterall, PhD | |
||
| Professor and Chair,University of Washington | |||
Ion
Channels as Therapeutic Targets | |||
10:15 | CNS Sodium Channel Defects and Epilepsy | |
|
| Alan Goldin, PhD | |
||
| Professor, University of California, Irvine | |||
10:45 | Refreshment Break and Poster Viewing | ||
11:00 | Alveolar Epithelial Cell Chloride Transport and the Resolution of Pulmonary Edema | |
|
| Scott O'Grady, PhD | |
||
| Professor, University of Minnesota | |||
11:30 | Ovarian Granulosa K+ Channels: Model Complexes, Novel Targets, or Safety Concern? | |
|
| Lisa Freeman, DVM, PhD | |
||
| Associate Professor, Kansas State University | |||
12:00 | Luncheon Break in Ballroom D | ||
1:30
| Pseudechetoxin - a probe for CNG ion channels | |
|
| Lane Brown, PhD | |
||
| Assistant Scientist, Neurological Sciences Institute | |||
Jun-11 | |||
8:30 | Registration & Breakfast Pastries with Coffee/Teas | ||
9:00
| Chairperson's Recap of Day Two | ||
| Tina Garyantes, PhD | |
||
| Head of Automated Screening, Aventis Pharmaceuticals | |||
Keynote
Address | |||
9:10 | Potassium Channels - The Wanted And Unwanted Targets | ||
| Min Li, PhD | |
||
| Associate Professor, Johns Hopkins School of Medicine | |||
Various
Approaches For Screening Ion Channels (Part II) | |||
10:15 | Cardiac Ion Channel Pharmacology and Structure-Function Analysis | ||
| Robert Spencer, PhD | |
||
| Senior Research Biochemist, Molecular Pharmacology Merck Research Laboratories | |||
10:45 | Refreshments and Poster Viewing | ||
11:00 | Drug-Acquired Long QT Syndrome and Preclinical Assays for Assessment of QT Liability | |
|
| Anthony Bahinski, PhD, MBA | |
||
| Senior Scientist, Pfizer, Worldwide Drug Safety Evaluation | |||
12:00 | Trinity of Assay Technologies for Ion Channels | ||
| Rolf Vajna, PhD | |
||
| Aventis Deutschland GmbH | |||
Note: all the presentations are in Zip format, please unzip(extract) the files to your hard drive first before opening them. If you don't have the WinZip program you can download it from here http://www.winzip.com/ | |||